carmoxirole has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greiner, HE; Haase, AF; Seyfried, CA | 1 |
| Frankenschmidt, A; Rump, LC; Schaible, U; Schollmeyer, PJ; Schuster, MJ; Schwertfeger, E | 1 |
2 other study(ies) available for carmoxirole and oxidopamine
| Article | Year |
|---|---|
Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.
Topics: Animals; Biogenic Amines; Brain; Clonidine; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Ergolines; Heart; Hypothalamus; Indoles; Levodopa; Male; Motor Activity; Norepinephrine; Oxidopamine; Pyridines; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reserpine; Sulpiride | 1991 |
Dopamine DA2-receptor activation inhibits noradrenaline release in human kidney slices.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Brimonidine Tartrate; Calcium; Dopamine Agents; Ergolines; Fenoldopam; Humans; In Vitro Techniques; Indoles; Kidney Cortex; Middle Aged; Norepinephrine; Oxidopamine; Pyridines; Quinoxalines; Quinpirole; Receptors, Dopamine D2; Sulpiride; Tetrodotoxin | 1993 |